September 30 - October 2, 2021   Virtual Event

Registration Information

Advance registration before 7:00 a.m.
on September 30 is required

for access to the Virtual Symposium. Late registrations may experience up to an hour delay in receipt of access to the virtual platform.

The registration fee includes conference tuition, CME credits, access to digital materials through October 24 and networking opportunities.

REGISTRATION FEES

Type Price
Physician $495
LMIC* Physician $100
Nurse/Nurse Practitioner/Fellow/Other Allied Health $125
LMIC* Nurse/Nurse Practitioner/Fellow/Other Allied Health $25
Industry $695

*Registrants who reside in LMIC countries as defined by the World Bank Group.

Refund/Cancellation Policy

Registration fees less a $50 administrative handling fee are refundable if a written request is received on or before August 30, 2021. Please include your registration ID number when requesting a refund. No refunds will be granted after August 30, 2021; however, you may transfer your registration to a colleague.

Inquiries

To submit requests or request further information, contact the Lurie Cancer Center at 312.503.7809 or e-mail us at cancer@northwestern.edu.

Related Links

Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Lynn Sage Breast Cancer Foundation


Sponsored by

Feinberg School of Medicine

Registration Desk

Learning Objectives

  1. Recognize social determinants of health that impact on breast cancer care
  2. Discuss the genomic differences between populations that explain variation in disease patterns and tolerance to treatment
  3. Summarize the impact of enhanced breast cancer risk assessment using multiple genomic markers
  4. Apply genomic assays to make treatments recommendations for adjuvant treatment in ER-positive, node-positive and node negative patient populations
  5. Describe surgical treatment options following breast recurrence in patient who previously underwent breast conservation therapy
  6. Discuss the opportunities and limitations of Next-generation sequencing (NGS)
  7. Discuss new systemic therapies for TNBC
  8. Summarize the current role of CDK4/6 inhibitors in early stage breast cancer

Target Audience

The target audience for this activity includes medical oncologists, radiation oncologists, surgical oncologists, fellows in training, oncology nurses and allied health professionals in breast cancer.

Accreditation Statement

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 18 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 18 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Credits

The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept AMA PRA Category 1 Credits(s)™ from organizations accredited by the ACCME.

Faculty Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation of financial interest that may affect the speaker's presentation. Each speaker has been requested to complete a faculty disclosure form. The names of faculty members declaring a relationship or who will be discussing off-label usage will be indicated in the course syllabus. All faculty will be disclosing.

© 2021 Robert H. Lurie Comprehensive Cancer Center